PUBLISHER: Grand View Research | PRODUCT CODE: 1587576
PUBLISHER: Grand View Research | PRODUCT CODE: 1587576
The global microbiome sample preparation technology market size is expected to reach USD 368.74 million in 2030 and is expected to expand at a CAGR of 6.09% from 2025 to 2030. The rising importance of the microbiome as an area of study for Inflammatory Bowel Disease (IBD) research along with the innovation in genome sequencing techniques are significant contributors to the market growth. Crohn's disease is one of the most common diseases of IBD and surging incidence rates in North America and Western Europe, with approximately 100 to 300 per 100,000 people being affected in both regions, are likely to accelerate the R&D for the same.
A metabolite-based treatment method is highly promising for Dysbiosis, despite its existing limitations. Within coming years, researchers are anticipated to require to incorporate metabolomics characterization of the microbial ecosystem into their standard toolkit, enabling the community to define functional signatures for disease states that have previously only been linked to compositional and metagenomic changes.
Additionally, the development of novel metabolite sensors will eventually allow for the targeted regulation of downstream signaling cascades in circumstances when the host's reaction to the microbiome is excessive. Metabolite-based treatments provide a direct and actionable way to combat the host effects of dysbiosis. The era of metabolite research in microbiome science has already begun, and sustained efforts could lead to the discovery of clinically applicable therapeutics for dysbiosis-related disorders.
Other factors such as the rising penetration of personalized medicine are likely to impact the usage of microbiome sample preparation technology. Various research institutes are conducting studies to understand the gut microbiome and its impact on diet followed by the identification of effective therapeutics. For instance, a study was carried out in 2019 at the Weizmann Institute of Science to develop an algorithm based on machine learning and study glycemic response after consuming similar food. The study concluded that patients displayed different glycemic responses, even when food consumed is the same as microbiome played an important determinant of the blood sugar levels than genetic data.
The COVID-19 pandemic accelerated the use of microbiome sample preparation technology for the research proposed. There have been various studies in progress focusing on the alteration of gut microbiome post-COVID-19 infection. According to studies, the abundance of phyla Firmicutes, Bacteroidetes, and Proteobacteria were observed within patients diagnosed with the virus. Furthermore, fecal metabolomic studies in COVID-19 patients have revealed probable amino acid-related pathways that link gut microbiota to inflammation.
However, the high cost of instruments in this market is anticipated to have adverse effects on the growth rate. Emerging nations with low spending capability on healthcare and sanitation are observed to have a high risk of gastrointestinal disorders. With the potential high risk of infection in the population, low penetration of technology within these regions is likely to act as a market restraint within specific countries.